Long-acting reversible contraception (update)

NICE guidelines [CG30] Published date:

Consultation on review proposal with stakeholders: 31 January 2011 - 13 February 2011

Review decision date: April 2014

Review decision: 

Publication of addendum update: September 3rd 2014.

This guideline should not be updated at this time. For further information, please refer to the Surveillance Review Decision

Next review date: December 2015

The NICE clinical guideline on long-acting reversible contraception (LARC) offers best-practice advice for all women of reproductive age who may wish to regulate their fertility using LARC methods. It covers specific issues for the use of these methods during the menarche and before the menopause, and by particular groups, including women who have HIV, learning disabilities or physical disabilities, or are younger than 16 years.

The addendum to NICE clinical guideline 30 updates the recommendations on progestogen-only subdermal implants in section 1.5 of the guideline. The addendum also contains details of the methods and evidence used to update these recommendations. The progestogen-only subdermal implant Implanon, previously recommended in this guideline, is no longer available and has been replaced by Nexplanon. Nexplanon contains the same amount of the same drug as Implanon, but the summaries of product characteristics for the two devices are not identical.

May 2013: Update of the recommendations on progestogen-only subdermal implants

The progestogen-only subdermal implant, Implanon, recommended in this guideline is no longer available.

Implanon was replaced by Nexplanon. Nexplanon contains the same amount of the same drug as Implanon, but the summaries of product characteristics for the two devices are not identical.

In the light of the change in the implant available, NICE will review the evidence and update the section of the guideline that makes recommendations on progestogen-only subdermal implants.

Healthcare professionals considering offering Nexplanon should consult the summary of product characteristics.

  • June 2006: The recommendation on treating irregular bleeding after insertion of a contraceptive implant has been changed (this is recommendation 1.5.4.2 in the NICE guideline). Although the evidence does show that mifepristone is effective at controlling irregular bleeding associated with implants, it is not licensed for this indication. The revised recommendation reads: 'Irregular bleeding associated with implant use can be treated with mefenamic acid or ethinylestradiol.'

  • Get involved